There is no specific course of treatment for leukemia with Vinaclat, and the efficacy is generally evaluated after each course of treatment. Vinaclat is a new type of anti-tumor targeted drugs, can to a certain extent to achieve the purpose of controlling leukemia, as a targeted drug, Vinaclat does not have a specific number of courses of treatment. If it is effective, patients can take it for more than one course of treatment, unless the disease progresses or intolerable side effects occur. The most common adverse reactions to taking Venekra are neutropenia, nausea, diarrhea, febrile neutropenia, constipation, thrombocytopenia, bleeding, peripheral edema, vomiting, fatigue, rash, and anemia. Women with tumor lysis syndrome, neutropenia, infections, and pregnancy should use this medication with caution. Venekra needs to be used under the supervision of a doctor.